Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

AI agents are powerful, but without a strong control plane and hard guardrails, they’re just one bad decision away from chaos.

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...

Merge lists even with typos and inconsistent names. Tune the similarity threshold, use a transform table, and audit results ...

1. Selected dates can't be greater than January 2026. 2. From date can't be greater than To date. 1. Selected dates can't be greater than January 2026. 2. From date can't be greater than To date. 1.